Vildagliptin (previously LAF237, trade names Galvus, Zomelis,) is an oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vildagliptin has been shown to reduce hyperglycemia in type 2 diabetes mellitus.
Send us your enquiry for Vildagliptin. We offer custom pack sizes at special prices. We aim to respond to your enquiry within 24 hours.
We value your input so if you have suggestions regarding new applications for Vildagliptin email us and we will include your contribution on the website.